Abstract
Ischemic stroke causes cell necrosis with the exposure of extracellular ribonucleic acid (RNA) and other intracellular material. As shown recently, extracellular RNA impaired the blood-brain-barrier and contributed to vasogenic edema-formation. Application of ribonuclease 1 (RNase 1) diminished edema-formation and also reduced lesion volume in experimental stroke. Here we investigate whether reduction of lesion volume is due to the reduction of edema or of other neuroprotective means. Neuroprotective and edema protective effects of RNase 1 pretreatment were assessed using a temporary middle cerebral artery occlusion (MCAO) model in rats. Lesion volume was assessed on magnetic resonance imaging (MRI). T2- relaxation-time and midline-shift as well as brain water content (wet-dry-method) were measured to quantify edema formation. The impact of edema formation on infarct volume was evaluated in craniectomized animals. Exogenous RNase 1 was well tolerated and reduced edema-formation and infarct size (26.7% ± 10.7% vs. 41.0% ± 10.3%; p < 0.01) at an optimal dose of 42 μg/kg as compared to placebo. Craniectomized animals displayed a comparable edema reduction but no reduction in infarct size. The present study introduces a hitherto unrecognized mechanism of ischemic brain damage and a novel neuroprotective approach towards acute stroke treatment.
Keywords: Acute stroke, edema, RNase, neuroprotection, craniectomy
Current Neurovascular Research
Title: RNase Therapy Assessed by Magnetic Resonance Imaging Reduces Cerebral Edema and Infarction Size in Acute Stroke
Volume: 6 Issue: 1
Author(s): Maureen Walberer, Marlene Tschernatsch, Silvia Fischer, Nouha Ritschel, Kai Volk, Carolin Friedrich, Georg Bachmann, Clemens Mueller, Manfred Kaps, Max Nedelmann, Franz Blaes, Klaus T. Preissner and Tibo Gerriets
Affiliation:
Keywords: Acute stroke, edema, RNase, neuroprotection, craniectomy
Abstract: Ischemic stroke causes cell necrosis with the exposure of extracellular ribonucleic acid (RNA) and other intracellular material. As shown recently, extracellular RNA impaired the blood-brain-barrier and contributed to vasogenic edema-formation. Application of ribonuclease 1 (RNase 1) diminished edema-formation and also reduced lesion volume in experimental stroke. Here we investigate whether reduction of lesion volume is due to the reduction of edema or of other neuroprotective means. Neuroprotective and edema protective effects of RNase 1 pretreatment were assessed using a temporary middle cerebral artery occlusion (MCAO) model in rats. Lesion volume was assessed on magnetic resonance imaging (MRI). T2- relaxation-time and midline-shift as well as brain water content (wet-dry-method) were measured to quantify edema formation. The impact of edema formation on infarct volume was evaluated in craniectomized animals. Exogenous RNase 1 was well tolerated and reduced edema-formation and infarct size (26.7% ± 10.7% vs. 41.0% ± 10.3%; p < 0.01) at an optimal dose of 42 μg/kg as compared to placebo. Craniectomized animals displayed a comparable edema reduction but no reduction in infarct size. The present study introduces a hitherto unrecognized mechanism of ischemic brain damage and a novel neuroprotective approach towards acute stroke treatment.
Export Options
About this article
Cite this article as:
Walberer Maureen, Tschernatsch Marlene, Fischer Silvia, Ritschel Nouha, Volk Kai, Friedrich Carolin, Bachmann Georg, Mueller Clemens, Kaps Manfred, Nedelmann Max, Blaes Franz, Preissner T. Klaus and Gerriets Tibo, RNase Therapy Assessed by Magnetic Resonance Imaging Reduces Cerebral Edema and Infarction Size in Acute Stroke, Current Neurovascular Research 2009; 6 (1) . https://dx.doi.org/10.2174/156720209787466037
DOI https://dx.doi.org/10.2174/156720209787466037 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Endocannabinoid System in Ageing: A New Target for Drug Development
Current Drug Targets Histone Deacetylase Inhibitors: Therapeutic Agents and Research Tools for Deciphering Motor Neuron Diseases
Current Medicinal Chemistry <i>In Vivo</i> Longitudinal Monitoring of Changes in the Corpus Callosum Integrity During Disease Progression in a Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Role of Immune Cells in the Course of Central Nervous System Injury: Modulation with Natural Products
Current Pharmaceutical Design Emerging Features in the Regulation of MMP-9 Gene Expression for the Development of Novel Molecular Targets and Therapeutic Strategies
Current Drug Targets - Inflammation & Allergy Astrocytic Expression of the Immunoreceptor CD300f Protects Hippocampal Neurons from Amyloid-β Oligomer Toxicity In Vitro
Current Alzheimer Research Biological Activities, Mechanisms of Action and Biomedical Prospect of the Antitumor Ether Phospholipid ET-18-OCH3 (Edelfosine), A Proapoptotic Agent in Tumor Cells
Current Drug Metabolism Depletion of Hypocretin/Orexin Neurons Increases Cell Proliferation in the Adult Subventricular Zone
CNS & Neurological Disorders - Drug Targets Src Family Kinases in the Central Nervous System: Their Emerging Role in Pathophysiology of Migraine and Neuropathic Pain
Current Neuropharmacology Optic Neuritis: A Model for the Immuno-pathogenesis of Central Nervous System Inflammatory Demyelinating Diseases
Current Immunology Reviews (Discontinued) Diverse Functions and Mechanisms of Pericytes in Ischemic Stroke
Current Neuropharmacology Targeting Gender Difference in the Introduction of New Drugs for Diabetes Mellitus and Metabolic Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Role for Poly(ADP-ribose) Polymerase Activation in Diabetic Nephropathy, Neuropathy and Retinopathy
Current Vascular Pharmacology Heme Oxygenase -1 Gene Therapy: Recent Advances and Therapeutic Applications
Current Gene Therapy Hypertension, Cognitive Impairment and Dementia: An Epidemiological Perspective
Current Hypertension Reviews Senescence of the Brain: Focus on Cognitive Kinases
Current Pharmaceutical Design Effects of Snake Venom Polypeptides on Central Nervous System
Central Nervous System Agents in Medicinal Chemistry In Vivo Cellular Imaging for Translational Medical Research
Current Medical Imaging Curcuminoids in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) TRPA1 and TRPM8 Receptors May Promote Local Vasodilation that Aggravates Oxaliplatin-Induced Peripheral Neuropathy Amenable to 17β-Estradiol Treatment
Current Neurovascular Research